Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
What happened
Shares of
Concert Pharmaceuticals (NASDAQ:CNCE) were cratering 28.9% as of 3:26 p.m. EST on Monday. The steep decline came after the company announced that experimental drug CTP-692 had failed to meet the primary and secondary endpoints in a phase 2 study as an adjunctive treatment for schizophrenia.
So what
It s always bad news for a clinical-stage biotech stock when a candidate fails in clinical testing. What s even worse for Concert is that CTP-692 was one of only two candidates in its pipeline.
December imports +0.9% y/y vs +4.13% in poll Full year 2020 exports +4.9% y/y, hit record high by value Finance ministry expects January exports +19% to +23% y/y Ministry sees “stable growth” for exports in Q1
TAIPEI, Jan 8 (Reuters) - Taiwan’s exports rose in December for the sixth consecutive month and at an unexpectedly strong pace, boosted by surging global demand for the island’s tech products amid the COVID-19 pandemic and new technologies like 5G.
Exports jumped 12% from a year earlier to $33 billion in December, the highest monthly figure on record, the Ministry of Finance said on Friday.
Analysts in a Reuters poll had forecast a rise of 9.2% for last month, compared with a 12% jump in November.